Rostam Osanlou
Overview
Explore the profile of Rostam Osanlou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu X, Munro A, Wright A, Feng S, Janani L, Aley P, et al.
J Infect
. 2023 Apr;
87(1):18-26.
PMID: 37085049
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were...
2.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2023 Apr;
86(5):540-541.
PMID: 37055303
No abstract available.
3.
Osanlou R, Walker L, Hughes D, Burnside G, Pirmohamed M
BMJ Open
. 2022 Jul;
12(7):e055551.
PMID: 35788071
Objective: To ascertain the burden and associated cost of adverse drug reactions (ADRs), polypharmacy and multimorbidity through a prospective analysis of all medical admissions to a large university teaching hospital...
4.
Munro A, Feng S, Janani L, Cornelius V, Aley P, Babbage G, et al.
Lancet Infect Dis
. 2022 May;
22(8):1131-1141.
PMID: 35550261
Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the...
5.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2022 Apr;
84(6):795-813.
PMID: 35405168
Objectives: To evaluate the persistence of immunogenicity three months after third dose boosters. Methods: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a...
6.
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D, et al.
Lancet
. 2021 Dec;
398(10318):2258-2276.
PMID: 34863358
Background: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we...
7.
Asiimwe I, Zhang E, Osanlou R, Jorgensen A, Pirmohamed M
Br J Clin Pharmacol
. 2020 Oct;
87(4):1717-1729.
PMID: 33080066
Aims: Numerous algorithms have been developed to guide warfarin dosing and improve clinical outcomes. We reviewed the algorithms available for various populations and the covariates, performances and risk of bias...
8.
Asiimwe I, Zhang E, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, et al.
Clin Pharmacol Ther
. 2019 Dec;
107(6):1420-1433.
PMID: 31869433
Warfarin is the most commonly used oral anticoagulant in sub-Saharan Africa. Dosing is challenging due to a narrow therapeutic index and high interindividual variability in dose requirements. To evaluate the...